4.10 USD
▲+0.20+1.99%
盘后 4.15 +3.23%
2026-08-03
市值
$165.62M
市盈率
—
EPS
-4.33
股息率
—
52 周区间
1.91 – 5.38
成交量
201.95K
Beta
—
目标价
19.50
52W 低 1.9152W 高 5.38
价格走势
公司简介
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Kα) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.